| 查看: 352 | 回复: 11 | |||
[交流]
【深容SCI写作智能体】Abstract实测
|
|||
|
【深容SCI写作智能体】Abstract实测 如需试用【深容SCI写作智能体】，请联系深容张老师：shenrongagent [https://scioriginal.com] 上月深容推出了【深容SCI写作智能体】的Method，Introduction，Discussion智能体，写作质量非常高，全部真实参考文献，深受用户欢迎。 今天介绍的Abstract写作智能体，功能相对简单，根据用户提供的正文内容，快速起草摘要，同时输出结构式摘要和一体式摘要。 1. 用户输入正文内容： 2. 检索参考同类题材的摘要格式： 3. 输出结果Abstract。 智能体的写作质量非常高： (1) Structured ABSTRACT 1) Background Signal Transducer and Activator of Transcription 2 (STAT2) is well-known for its role in type I interferon (IFN-I) signaling, which is generally considered tumor-suppressive. However, its direct role in cancer, particularly colorectal cancer (CRC), remains underexplored. Given the critical involvement of immune and cytokine networks in CRC progression, elucidating STAT2's contribution is essential. 2) Methods We analyzed TCGA-COAD datasets to assess STAT2 and IFNAR1 expression and patient survival. Human HCT116 and murine MC38 cell lines with STAT2 or IFNAR1 knockouts were generated using CRISPR\/Cas9 technology. Cell proliferation was measured in vitro using the CellTiter 96 assay. In vivo tumor growth was evaluated by subcutaneous injection of knockout and control cells into immunodeficient or immunocompetent mice. Western blot and qPCR analyses were performed to assess downstream signaling and gene expression changes. 3) Results High STAT2 expression in TCGA-COAD tumors correlated with reduced patient survival, independent of IFNAR1 levels. STAT2 deletion impaired cell proliferation and tumor growth in both human and murine models, whereas IFNAR1 deletion did not. STAT2 KO cells exhibited reduced STAT1 activation but enhanced STAT3 phosphorylation, indicating distinct downstream signaling effects compared to IFNAR1 KO cells. These findings suggest that STAT2 promotes tumorigenicity through mechanisms distinct from canonical IFN-I signaling. 4) Conclusion Our study reveals that STAT2 functions as a tumor-promoting factor in CRC, acting independently of IFNAR1-mediated IFN-I signaling. Targeting STAT2 or its downstream pathways may offer a novel therapeutic strategy for mitigating CRC progression. --- (2) Integrated ABSTRACT Signal Transducer and Activator of Transcription 2 (STAT2) is a key mediator of type I interferon (IFN-I) signaling, traditionally viewed as tumor-suppressive. However, its direct role in colorectal cancer (CRC) remains poorly defined, despite the critical influence of immune and cytokine networks on disease progression. To address this gap, we analyzed TCGA-COAD datasets and found that high STAT2 expression in CRC tumors correlated with reduced patient survival, independent of IFNAR1 levels. Using CRISPR\/Cas9 technology, we generated human HCT116 and murine MC38 cell lines with STAT2 or IFNAR1 knockouts. In vitro cell proliferation assays demonstrated that STAT2 deletion significantly impaired growth, whereas IFNAR1 deletion had no effect. In vivo studies in immunodeficient and immunocompetent mice confirmed that STAT2 KO cells formed smaller tumors compared to controls, while IFNAR1 KO cells did not differ significantly from wild-type cells. Western blot and qPCR analyses revealed that STAT2 deletion reduced STAT1 activation but enhanced STAT3 phosphorylation, indicating distinct downstream signaling effects compared to IFNAR1 KO cells. These findings suggest that STAT2 promotes tumorigenicity through mechanisms independent of canonical IFN-I signaling. Our study highlights STAT2 as a potential therapeutic target in CRC, offering new avenues for mitigating disease progression by targeting its pro-tumorigenic pathways. 以上这篇Abstract起草时间仅00:01:35 【深容SCI写作智能体】包括四大模块：Method智能体、Introduction智能体、Discussion智能体、Abstract智能体。 如需试用智能体，请徽售联系深容张老师：shenrongagent [https://scioriginal.com] #SCI论文 #科研 #实验 #博士 #投稿     |
回复此楼» 猜你喜欢
二苯甲酮酸类衍生物
已经有4人回复
-
一志愿中科大材料与化工，353分还有调剂学校吗
已经有11人回复
-
294求调剂
已经有6人回复
-
335求调剂
已经有23人回复
-
279求调剂
已经有13人回复
-
304求调剂
已经有6人回复
-
322求调剂
已经有3人回复
-
271求调剂
已经有39人回复
-
收到复试调剂但是去不了
已经有6人回复
-
有没有接收比较快的sci期刊呀，最好在一个月之内的，研三孩子求毕业
已经有5人回复
» 抢金币啦！回帖就可以得到:
-
广东石油化工学院环境工程专业硕士生，大类07，08，09都可以调剂，先到先得！
+1/492
-
辽石化新材料学院材料专业调剂 理转工 / 学专互调
+1/477
-
不寻找搭子，寻一位，深圳合伙人
+1/274
-
感谢小木虫的平台，来散金币，祝小木虫越来越好。
+2/142
-
双一流南京医科大学招计算机、生物信息等方向研究生调剂
+1/135
-
上海脱单，一个不算完美但足够真实的男生，期待认识你
+5/45
-
坐标河北邢台，征女友
+1/36
-
山东航空学院安全工程专业085702第三轮接收研究生调剂，欢迎咨询
+1/35
-
瑞典 Linköping University 诚聘 氮化物基无机材料方向 博士后1名
+1/31
-
大连海洋大学资源与环境专硕（0857）接收调剂学生
+1/15
-
中科院大连化物所/香港城市大学招聘联合培养优秀博士后人才
+2/14
-
稀土发光分析｜核壳结构｜寿命拟合
+1/10
-
省重点实验室招收07专业调剂生，海洋生物专业名额充足
+1/8
-
佛山大学动物科技学院2026年硕士研究生招生调剂公告（第三批）
+1/8
-
深圳理工大学博士后招聘-先进拉曼技术课题组
+1/7
-
招收调剂生（一志愿07开头专业），海洋生物专业4个名额
+1/7
-
基金祈福
+1/5
-
与其发展宠物经济，不如改变年轻人的婚恋观
+1/3
-
沈阳农业大学-北京协和医学院药用植物研究所联合培养硕士招生（调剂招生）
+1/1
-
华南理工大学微电子学院博士招生（射频模拟混合信号芯片、天线超表面/AI方向）
+1/1
简单回复
夏末末872楼
2026-01-11 18:20
回复
pheiphei2025(金币+1): 谢谢参与
1 发自小木虫手机客户端
2026-01-11 18:31
回复
jiaoxg4楼
2026-01-11 18:39
回复
pheiphei2025(金币+1): 谢谢参与
tfang5楼
2026-01-11 18:42
回复
pheiphei2025(金币+1): 谢谢参与
2026-01-11 18:51
回复
pheiphei2025(金币+1): 谢谢参与
2026-01-11 19:04
回复
toppaper8楼
2026-01-11 20:07
回复
XG-WUST9楼
2026-01-11 21:35
回复
pheiphei2025(金币+1): 谢谢参与
up 发自小木虫IOS客户端
psylhh10楼
2026-01-11 22:21
回复
pheiphei2025(金币+1): 谢谢参与
庚辰辛丑11楼
2026-01-12 07:28
回复
pheiphei2025(金币+1): 谢谢参与
afit88812楼
2026-01-12 11:17
回复
